Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

| Filed by the Registrant ⌧                    |                                                                                 |
| Filed by a Party other than the Registrant ◻ |                                                                                 |
| Check the appropriate box:                   |                                                                                 |
| ◻                                            | Preliminary Proxy Statement                                                     |
| ◻                                            | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ⌧                                            | Definitive Proxy Statement                                                      |
| ◻                                            | Definitive Additional Materials                                                 |
| ◻                                            | Soliciting Material under §240.14a-12                                           |

| ​                                                                        |                                                                                                     |
| AbbVie Inc.                                                              |                                                                                                     |
| (Name of Registrant as Specified In Its Charter)                         |                                                                                                     |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |                                                                                                     |
| Payment of Filing Fee (Check the appropriate box):                       |                                                                                                     |
| ⌧                                                                        | No fee required.                                                                                    |
| ◻                                                                        | Fee paid previously with preliminary materials.                                                     |
| ◻                                                                        | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

| Notice of 2025   
 Annual Meeting   
 of Stockholders​ |

To the stockholders of our company: You are cordially invited to attend the 2025 Annual Meeting of Stockholders to be held on May 9, 2025, where we will be voting on the below matters. You will be able to attend the Annual Meeting, vote, and submit questions via live webcast by visiting www.virtualshareholdermeeting.com/ABBV2025. Items of business

| ● | To elect four directors to hold office until the 2028 Annual Meeting or until their successors are elected. |

| ● | To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2025. |

| ● | To vote on an advisory basis on the approval of executive compensation. |

| ● | To vote on a management proposal to eliminate supermajority voting. |

| ● | To consider any other matters that may properly come before the meeting, including one stockholder proposal, if